Immunosuppressive treatment of patients with idiopathic membranous nephropathy is controversial because of the toxicity of the therapy and the variable natural course of the disease. In this Review, the authors discuss the 2012 Kidney Disease: Improving Global Outcomes guideline for the treatment of patients with idiopathic membranous nephropathy and highlight the remaining areas of uncertainty.
- Julia M. Hofstra
- Fernando C. Fervenza
- Jack F. M. Wetzels